Neha Venkatesh

Hematology/Oncology Fellow @UCSFCancer

[Arpita Desai @ADESAIONCMD]

What an absolute honor to chair the papillary RCC Education Session at #ASCO26! 🙌🔬

Papillary renal cell carcinoma is a disease that demands our attention, and this session covered the full spectrum 🧬 — biology ➡️ frontline ➡️ refractory disease.

I was thrilled to review subsequent lines + novel therapeutic approaches for refractory papillary RCC 💉💙, including the emerging strategies and clinical trial opportunities that give me so much hope for our patients. 🌟

Huge thanks to my incredible co-faculty Dr. Ramaprasad Srinivasan 🧠 & @charlesbnguyen for such an engaging discussion — collaboration like this is what moves the field forward! 🚀

#KidneyCancer #RCC #GUOncology @ASCO @urotoday @JCO_ASCO @ASCOPost @charlesbnguyen @OncoAlert @UCSF

[Tanya Dorff @TDorffOnc]

Congrats to Dr Armstrong and colleagues for CHAMP study showing quadruplet chemo immunotherapy results in much better outcomes for patients with AVPC and teNEPC - need more trials for these most aggressive #prostatecancer #ASCO26

[Uromigos @Uromigos]

Unsung hero poster award for RCC. @OncHahn discusses muscle and fat changes in patient receiving either Len/Ev or Cabo with some interesting findings that complement standard toxicity data.

[Daniel E Spratt @DrSpratticus]

#ASCO26
The PROTEUS trial results are now online...buckle up as we wait to see the full presentation. This is going to be a trial that is likely highly controversial until the full results are published.

Some may call this a homerun, others may call this the largest negative trial @ASCO 2026. Up to you to interpret!

@urotoday @EricTopol @DrChoueiri @neerajaiims @ASCO @US_FDA @NCCN @myESMO @ASTRO_org @PCF_Science @declangmurphy @mcuban

[Ana I. Velázquez Mañana, MD, MSc, FASCO @AnaVManana]

🎉 #ASCO26 Plenary Session with @UCSFCancer Dr. Eric Small @ASCOPres and Dr. Jo Chien

#UCSFproud

[Andy Hahn @OncHahn]

Great combo of presys by Dr. Mateo and @neerajaiims show ADT + enza + tala improves rPFS for APMS prostate cancer and how ADT + enza induces transcriptome changes but not HRD

[Sumanta K. Pal, MD, FASCO @montypal]

Cheers to @neerajaiims on his presentation of the #TALAPRO3 data w simultaneous @NEJM publication! It reflects the dream of many clinical investigators in #oncology - to lead a trial & generate paradigm shifting data in a field that you have devoted your life to (in this case, #prostatecancer).

If you see him at #ASCO26, inquire about his remarkable story. At @huntsmancancer, he built the GU program from scratch into one of the highest performing programs worldwide. He did this over the span of nearly two decades through mentorship of his faculty & fellows (@umangtalking @maughanonc @ziremozay @ggebraelmd et al), extensive outreach to the local community & active participation & leadership in multiple studies (a mix of industry, ISTs & @SWOG). Simply amazing.

[The Intima @The_Intima]

When a doctor becomes a patient, we witness a different kind of illness narrative: one that opens up the 'clinical encounter' in a whole different way. Lucky for us as patients and lucky for clinicians too, @RanaAwdish opens our eyes + minds once again when her new book "After Shock" comes out in June.
Honored to have her essay in our new anthology too!

[Andy Hahn @OncHahn]

(1/3) Here is our clinical lab’s latest work on how body composition influences the efficacy of nivo + ipi for pts with metastatic ccRCC https://t.co/V1wx3eXzrg in @jitcancer Led by @kgre23 @MourattJulia and collab with @PavlosMsaouel lab

[Tanya Jindal @TanyaJindal97]

UNITE study analysis @ASCO #GU26 evaluating prior IO exposure and outcomes with EVP in aUC:
68 had prior IO
⬇️PFS: 6.7 vs 11.7 months (HR 1.60)
⬇️ OS: 13.3 vs 21.9 months (HR 1.53)
IO–EVP interval not associated with improved outcomes
Important considerations for sequencing

[Mitchell Boshkos @MitchellBoshkos]

Great few days at @ASCO GU in San Francisco.

Grateful to my mentor @OncHahn and the incredible GU team at @MDAndersonNews for the opportunity and support

#ASCOGU #ProstateCancer #GUOncology #MDAnderson

[Matt Campbell MD, MS @DocMattCampbell]

At #GU26 a tremendous overview of optimal trial design by @PavlosMsaouel. Pavlos has repeatedly shown that even in very rare cancers, optimally designed studies can rapidly led to practice changing findings. A visionary in our field.

[Andy Hahn @OncHahn]

Congrats to @NazliDizman on her RCC posters studying grade 4 RCC outcomes with nivo + ipi and an ongoing trial of ivonescimab #ASCOGU26 @MDAndersonNews

[Andy Hahn @OncHahn]

Great work by @MitchellBoshkos @kgre23 and @MourattJulia on their work investigating how cardiometabolic factors influence the efficacy of APM in men with localized and metastatic APMN prostate cancer #ASCOGU26 @BCM_InternalMed

[Vadim Koshkin MD @koshkin85]

Looking forward to this in just a couple of days @asco #GU26 @UCSFCancer @UCSFUrology @UCSFMedicine

[GU Oncology Now @GUOncologyNow]

⭐ Take a look at our deep dive on @UCSFCancer's multidisciplinary approach to #bladdercancer care: https://t.co/bwS6PBlwG9

📺 We spoke with multiple experts across the spectrum of care, including @xiaolin_zhu, @CChuMD, @thomashopemd, and more.

[Nazli Dizman @NazliDizman]

💫Wonderful to join @thenasheffect @ASCO and this fantastic lineup of panelists to discuss one of the most important aspects of professional development.

😇Really looking forward to sharing my my experience and highlight the amazing #mentors #sponsors #frientors who’ve played such a big role in my journey.

🔗Register https://t.co/Ic18TVx47o
⏰1/30 Fri 8:30 am CST

@RyanNipp @cspramesh @IshwariaMD @Betzabe100 @OAlhalabiMD @montypal @crisbergerot @DrChoueiri @DrYukselUrun @ReginaBarCar #MedEd #MedTwitter @AnaVManana @AmandaNizamMD @ASCOTECAG @IMG_Oncologists

[Mustafa Saleh @Mustafajsalehmd]

Setting the stage framing it clearly for the rest of the session - - @koshkin85 maps out in a clyster clear way the histologic subtypes and molecular landscape + what’s actionable today.

#AUC3 #BladderCancer
@AUC3_Official @OncoAlert @mzugman @MichalSternsch @weoncologists

[Martha Mims @marthamims]

Very proud of Mitch and Kelly and their ASH abstract achievement award! Future looks bright for hematology!!

[Kelly Meza, MD @KellyMezaMD]

I am deeply grateful to share that I matched at @MDAndersonNews 🙌🌟

This journey has been made even more meaningful by the incredible #mentors who guided me and the amazing #faculty I interacted with during my fellowship interviews.

Thanks to all programs for the opportunity!